ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

5-Methylcytosine Related LncRNAs Reveal Immune Characteristics, Predict Prognosis and Oncology Treatment Outcome in Lower-Grade Gliomas

Zhang, Jiheng; Wang, Nan; Wu, Jiasheng; Gao, Xin; Zhao, Hongtao; Liu, Zhihui; Yan, Xiuwei; Dong, Jiawei; Wang, Fang; Ba, Yixu; Ma, Shuai; Jin, Jiaqi; Du, Jianyang; Ji, Hang*; Hu, Shaoshan*哈尔滨医科大学
Frontiers in Immunology2022-3-3DOI: 10.3389/fimmu.2022.844778
15被引8阅读
引用收藏
分享

摘要

5-Methylcytosine (m5C) methylation is an important RNA modification pattern that can participate in oncogenesis and progression of cancers by affecting RNA stability, expression of oncogenes, and the activity of cancer signaling pathways. Alterations in the expression pattern of long non-coding RNAs (lncRNAs) are potentially correlated with abnormalities in the m5C regulation features of cancers. Our aim was to reveal the mechanisms by which lncRNAs regulated the m5C process, to explore the impact of aberrant regulation of m5C on the biological properties of lower-grade gliomas (LGG), and to optimize current therapeutic. By searching 1017 LGG samples from the Cancer Genome Atlas and Chinese Glioma Genome Atlas, we first clarified the potential impact of m5C regulators on LGG prognosis in this study and used univariate Cox analysis and least absolute shrinkage and selection operator regression to explore clinically meaningful lncRNAs. Consequently, we identified four lncRNAs, including LINC00265, CIRBP-AS1, GDNF-AS1, and ZBTB20-AS4, and established a novel m5C-related lncRNAs signature (m5CrLS) that was effective in predicting prognosis. Notably, mutation rate, WHO class II, IDH mutation, 1p/19q co-deletion and MGMT promoter methylation were increased in the low m5CrLS score group. Patients with increased m5CrLS scores mostly showed activation of tumor malignancy-related pathways, increased immune infiltrating cells, and decreased anti-tumor immune function. Besides, the relatively high expression of immune checkpoints also revealed the immunosuppressed state of patients with high m5CrLS scores. In particular, m5CrLS stratification was sensitive to assess the efficacy of LGG to temozolomide and the responsiveness of immune checkpoint blockade. In conclusion, our results revealed the molecular basis of LGG, provided valuable clues for our understanding of m5C-related lncRNAs, and filled a gap between epigenetics and tumor microenvironment.

学科与关键词

关键词
5-methylcytosinelong non-coding RNAsimmuneoncology treatmentlower-grade gliomas
相关
加载中…
  • Using integrated analysis from multicentre studies to identify RNA methylation-related lncRNA risk stratification systems for glioma
    Huang, Fanxuan; Wang, Xinyu; Zhong, Junzhe; Chen, Hao; Song, Dan; Xu, Tianye; Tian, Kaifu; Sun, Penggang; Sun, Nan; Qin, Jie; Song, Yu; Ma, Wenbin; Liu, Yuxiang; Yu, Daohan; Meng, Xiangqi; Jiang, Chuanlu; Xuan, Hanwen; Qian, Da*; Cai, Jinquan*Cancer Cell International, 2023, 23(1): 156.
  • Machine learning-based screening of an epithelial-mesenchymal transition-related long non-coding RNA signature reveals lower-grade glioma prognosis and the tumor microenvironment and predicts antitumor therapy response
    Wang, Nan; Gao, Xin; Ji, Hang; Ma, Shuai; Wu, Jiasheng; Dong, Jiawei; Wang, Fang; Zhao, Hongtao; Liu, Zhihui; Yan, Xiuwei; Li, Bo; Du, Jianyang*; Zhang, Jiheng*; Hu, Shaoshan*Frontiers in Molecular Biosciences, 2022, 9: 942966.
  • Integrated analysis of genome-wide DNA methylation and cancer-associated fibroblasts identified prognostic biomarkers and immune checkpoint blockade in lower grade gliomas
    Dong, Jiawei; Wang, Fang; Gao, Xin; Zhao, Hongtao; Zhang, Jiheng; Wang, Nan; Liu, Zhihui; Yan, Xiuwei; Jin, Jiaqi; Ba, Yixu; Ma, Shuai; Du, Jianyang; Ji, Hang*; Hu, Shaoshan*Frontiers in Oncology, 2023, 12: 977251.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2022-03-03
卷期
第 13 卷
页码
844778
DOI
10.3389/fimmu.2022.844778
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [61575058]

作者

  • Z

    Zhang, Jiheng (第一作者)

    zhejiang prov peoples hosp · 2 · harbin med univ

  • W

    Wang, Nan

    zhejiang prov peoples hosp · 2 · harbin med univ

查看全部 15 位作者收起作者
  • W

    Wu, Jiasheng

    2 · harbin med univ

  • G

    Gao, Xin

    2 · harbin med univ

  • Z

    Zhao, Hongtao

    zhejiang prov peoples hosp · 2 · harbin med univ

  • L

    Liu, Zhihui

    zhejiang prov peoples hosp · 2 · harbin med univ

  • Y

    Yan, Xiuwei

    zhejiang prov peoples hosp · 2 · harbin med univ

  • D

    Dong, Jiawei

    2 · harbin med univ · zhejiang prov peoples hosp

  • W

    Wang, Fang

    zhejiang prov peoples hosp · 2 · harbin med univ

  • B

    Ba, Yixu

    2 · harbin med univ

  • M

    Ma, Shuai

    2 · harbin med univ

  • J

    Jin, Jiaqi

    2 · harbin med univ

  • D

    Du, Jianyang

    shandong prov hosp

  • J

    Ji, Hang (通讯)

    2 · harbin med univ · zhejiang prov peoples hosp

  • H

    Hu, Shaoshan (通讯)

    zhejiang prov peoples hosp · 2 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417